Enzolytics, Inc. Announces Production and Sale in North America of "Enzolytics IPF Immune", a Tested Immune Modulator based on U.S. Patent No. 8,309,072
Wednesday, November 17, 2021 8:00 AM
Share this article now
Topic: Company Update
Enzolytics, Inc.
Enzolytics, Inc.
COLLEGE STATION, TX / ACCESSWIRE / November 17, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) has announced planned production and sale in the U.S. and North America of "Enzolytics IPF Immune", a liquid nutritional supplement that is an immune modulator that benefits the immune system by fortifying it against infections and supporting the body's antioxidant defense. The active components in the supplement have been registered with the FDA for use in the U.S. under NDI reg. no. 1083. The product will be produced and sold by the Company pursuant to its license under U.S. Patent No. 8,309,072 (the ‘072 Patent).
This ‘072 Patent, entitled "Irreversibly-Inactivated Pepsinogen Fragments for Modulating Immune Function", covers the use of Irreversibly Inactivated Pepsin Fragments (IPF) which has been shown in tests to perform an immune modulating function. The primary IPF ingredient is a complex platform that modulates the immune system and may be used alone or as a concomitant therapy for a variety of diseases. The IPF active substance in the product is derived from pepsin from the mucosa, and the method of its extraction and application is the subject of the licensed ‘072 Patent invented by the Company's Chief Scientific Officer Harry Zhabilov. The immune modulator is made from purified, and lyophilized pepsin containing a polypeptide chain of 327 amino acid residues and one phosphoric acid residue. Using a proprietary method, a peptide chain of 36 amino acids - (IPF) is isolated and made available in a ready-to-use liquid form.
In tests, this therapeutic has demonstrated significant beneficial effects for various diseases, whether used alone or as a concomitant therapy, by bolstering the immune system. The irreversible pepsin fraction (IPF) in Enzolytics IPF Immune effectively inhibits the infectious HSV-1 viral progeny without toxicity to cells. The viral yield in tested subjects was also reduced. In addition, IPF, based on HSV-1 and CoV-Sars-2 reports, has shown antiviral effects.
The Company's 15-year license to the ‘072 patent grants to Enzolytics marketing rights in all U.S. states, territories, provinces, North American countries and Australia. The Company is moving forward with production of the product and with nationwide distribution throughout the licensed territory.
The Company Chief Scientific Officer, Harry Zhabilov, stated: "We see this product as significant to our focus on providing effective therapeutics for treating infectious diseases and are proud to bring to the U.S. and North American markets a product that has been tested and previously successfully marketed abroad. Over many years, I have been intimately involved in its invention, development and prior testing. To be able to bring it to the North American continent is a meaningful achievement of which we are extremely proud."
The Company CEO, Charles Cotropia, stated: "The North America dietary supplements market size is large, valued at over $50 Billion in 2020 and expected to grow at a compound annual growth rate of 5.6% over each of the next 5 years. Consumers are increasingly aware of the significance of personal health and wellbeing and this awareness is driving the market. Enzolytics IPF Immune will play a significant role in this space and due to its beneficial effects, it will be well received. It is a significant addition to the multiple therapeutics our company is producing."
News 
Market Data 
Discover 
AI
